The Allspring Mid Cap Growth Fund delivered strong results in the fourth quarter of 2025, surpassing the Russell Midcap Growth Index. For the Institutional Class shares, the gross expense ratio stands at 0.91%, while the net expense ratio is 0.85%.
Quarterly Performance Overview
Analysis of the quarter reveals robust contributions from key holdings. The fund benefited from targeted investments in high-growth mid-cap companies, driving outperformance amid market volatility.
Standout Holdings
Teva surpassed revenue forecasts and implemented significant cost reductions. These improvements led S&P to upgrade its credit rating, signaling stronger financial health.
Natera leads in molecular diagnostics with its Signatera platform, a liquid biopsy test designed to detect minimal residual disease. Adoption of this technology has accelerated sharply, boosting the company’s momentum.
Management anticipates sustained double-digit revenue expansion, aiming for more than 20% growth in adjusted EPS. This outlook relies on strategic acquisitions and enhanced vertical integration to fuel long-term gains.
